| At a Glance | |
|---|---|
| Comparison | rTMS (repetitive transcranial magnetic stimulation) vs intranasal esketamine (Spravato) for treatment-resistant depression (TRD) |
| Best available evidence | Individual participant data pooled from THREE-D (rTMS) and TRANSFORM-2 (esketamine) — Kaster et al., eClinicalMedicine 2025 (PMID 41245530) |
| Headline finding | Both beat a new oral antidepressant; rTMS had a non-significant numerical edge in MADRS reduction at week 4 (−2.46 points, 95% CI −5.82 to 0.89) |
| Safety edge | rTMS associated with lower hospitalisation risk and lower arrhythmia risk in a 2025 target-trial emulation (PMID 41506390) |
| Speed | Esketamine: measurable effect within 24 hours. rTMS: clinical response typically at 2–4 weeks |
| Esketamine as stand-alone? | No — not a long-term monotherapy; clinical role is acute bridge or short-term adjunct to TMS |
| Bottom line | rTMS for most TRD patients; esketamine reserved for acute suicidal crises or as a time-limited bridge in the opening weeks of a TMS course |
For decades, clinicians treating patients whose depression has failed two or more adequate antidepressant trials had little beyond switching drug classes or adding lithium augmentation. The approval of intranasal esketamine (Spravato) by the FDA in 2019 and the already-established evidence base for repetitive transcranial magnetic stimulation (rTMS) changed that picture. By 2025, both treatments were routinely offered at academic medical centres. What was missing was a rigorous comparison. That gap started to close in late 2025 when a team led by Tarek Kaster at the University of Toronto published the first individual participant data (IPD) analysis directly pitting rTMS against intranasal esketamine for treatment-resistant depression.
This article reviews that evidence and places it in clinical context — including the critical point that esketamine is not, and should not be marketed as, a stand-alone treatment strategy.
If you are in immediate danger, please contact emergency services or a crisis line in your country. The clinical discussion below is for patients stable enough to plan care with their treating physician.
Why This Comparison Took So Long
Treatment-resistant depression is typically defined as failure of at least two antidepressant trials at adequate dose and duration. It affects roughly 30% of patients diagnosed with major depressive disorder. Both rTMS and intranasal esketamine were approved for this indication, yet no randomised head-to-head trial had compared them.
The reasons are partly commercial — Janssen (esketamine) and academic TMS programmes have no shared incentive to run a competitor trial — and partly methodological. The patient populations eligible for each treatment differ somewhat: esketamine trials excluded patients with psychotic features and substance misuse more strictly, while TMS trials have traditionally excluded patients with active suicidal ideation.
The only way to approximate a comparison was to pool individual-level data from trials that had used the same outcome measure, the Montgomery-Åsberg Depression Rating Scale (MADRS), and similar inclusion criteria. The THREE-D trial (Blumberger et al., Lancet 2018; PMID 29726344) provided the rTMS arm; the TRANSFORM-2 trial (Popova et al., Am J Psychiatry 2019; PMID 31109201) provided the esketamine arm.
What the 2025 IPD Analysis Found
Kaster and colleagues’ IPD analysis (PMID 41245530), published in eClinicalMedicine (Lancet group) on 30 October 2025, matched participants across both trials using propensity weighting and estimated the treatment effect on MADRS total score at week 4.
Key findings:
- Both rTMS and intranasal esketamine were significantly more effective at reducing MADRS scores than switching to a new oral antidepressant — confirming what clinicians had largely assumed from the original trials.
- rTMS produced a non-statistically significant numerical advantage over esketamine: a mean MADRS difference of −2.46 points (95% CI −5.82 to 0.89, p = 0.14). The confidence interval crosses zero, so no superiority can be claimed.
- Response and remission rates were directionally similar across the two arms after propensity adjustment.
The authors are explicit about limitations: eligibility differences between the two original trials introduce residual confounding that cannot be fully removed by statistical adjustment. Outcomes were measured only to week 4 — before many patients reach maximal rTMS benefit, since standard protocols run 4–6 weeks and accelerated protocols are still being optimised. The authors call for a prospective head-to-head randomised trial, which does not yet exist.
What the analysis does establish is that neither treatment is dramatically superior to the other on a population basis at four weeks, and that both are genuinely more effective than the standard clinical alternative of trying another antidepressant.
Real-World Comparative Effectiveness: Hospitalization, Safety, and Durability
A second 2025 study (PMID 41506390), using a target-trial emulation design on observational data from 2019–2025, adds a safety dimension the IPD analysis could not capture.
Patients starting rTMS had a lower risk of psychiatric hospitalisation compared with those starting intranasal esketamine (hazard ratio 0.746, 95% CI 0.646–0.861). They also showed lower rates of arrhythmia and accidental injury — adverse events that have been documented in post-marketing surveillance data for esketamine.
On one measure esketamine had a marginal advantage: the risk of a suicide-related event was lower with esketamine at 30–90 days (HR 1.496 favouring esketamine on that sub-interval), consistent with its faster onset of action. This is clinically meaningful for the specific scenario of an acutely suicidal patient who needs rapid stabilisation before rTMS has time to build effect.
A smaller retrospective real-world study comparing accelerated rTMS (n = 18) with intranasal esketamine (n = 22) found notably higher response (72.2% vs 20%, p < 0.001) and remission rates (66.6% vs 10%, p = 0.003) at one month in the rTMS group (PMID 41814584). By three to six months, outcomes converged — suggesting that esketamine may catch up over a longer observation window, or that patients who respond to esketamine have largely responded by then. This study is small and retrospective; it cannot be the basis for firm clinical conclusions, but the direction is consistent with the other datasets.
Clinical Differences That Numbers Do Not Fully Capture
Speed of onset. Esketamine produces measurable antidepressant effects within 24 hours and sometimes within two to four hours of administration. rTMS produces clinical response over two to four weeks, with some patients not reaching maximum benefit until week six. This difference is irrelevant for a patient who can wait; it is decisive for a patient in acute suicidal crisis.
Side-effect profile. Esketamine’s most common adverse effects are dissociation (reported in 25–60% of treated sessions), nausea, dizziness, and sedation. Because of the dissociative risk and abuse potential, FDA regulations require patients to be monitored for at least two hours post-administration in a certified healthcare setting. Patients cannot drive on the day of treatment. rTMS’s principal side effects are headache and local scalp discomfort, which typically diminish after the first week. Serious adverse events are rare; the main absolute contraindication is metallic implants near the coil field.
Mechanism and durability. rTMS remodels prefrontal-limbic circuits through repeated stimulation. The effect is structural in character — it leverages long-term potentiation in neural networks — and in responders tends to be durable for six to twelve months or longer. Esketamine works primarily through rapid NMDA receptor antagonism with downstream AMPA potentiation and BDNF release, producing synaptic strengthening that is real but time-limited. Without maintenance dosing (twice-weekly for weeks, then weekly or bi-weekly), most patients who respond to esketamine relapse within days to weeks after stopping.
Practical access. A standard rTMS course runs approximately 20–36 sessions over four to six weeks, typically available at academic medical centres and specialist neurostimulation clinics. Intranasal esketamine is administered at certified Spravato treatment centres; the requirement for supervised on-site dosing limits spontaneous access and has implications for employment and scheduling.
Patient Selection: Who Benefits from Which Approach?
Clinical decision-making should integrate several factors that the population-level trials do not resolve:
Favour rTMS when:
- The patient can wait two to four weeks for effect
- Durability is the primary goal — rTMS response tends to outlast esketamine response without ongoing treatment
- The patient has a history of substance misuse, dissociative episodes, or cardiovascular disease (where esketamine’s haemodynamic effects carry greater risk)
- qEEG or functional neuroimaging has identified a prefrontal network target amenable to magnetic stimulation
- The patient cannot reliably attend a monitored dosing clinic twice weekly
Favour esketamine (as a bridge or adjunct, not monotherapy) when:
- Acute suicidal ideation is present and rapid stabilisation is needed in the days before rTMS response builds
- The patient is commencing an rTMS course and needs short-term relief during the induction window (see: Ketamine as a Bridge to TMS)
- Previous rTMS courses have failed and an acute trial of esketamine may guide whether NMDA-pathway mechanisms are relevant
Why Esketamine Is Not a Stand-Alone Long-Term Strategy
The commercial framing of esketamine — a convenient nasal spray that can be administered bi-weekly at an outpatient setting — has led some practitioners to position it as a maintenance monotherapy. The evidence does not support this role.
The SUSTAIN-2 open-label trial showed that among patients who had responded to esketamine induction, discontinuation led to relapse in roughly half within two months. Long-term esketamine dependence carries unresolved safety questions: abuse potential (esketamine is structurally identical to ketamine, a controlled substance), effects on bladder and urinary tract with chronic use, and the impact of repeated dissociative episodes on cognition and wellbeing.
For most patients with treatment-resistant depression, the durable, non-addictive, circuit-level intervention is rTMS. Esketamine’s clinical value lies precisely in what it does uniquely well: rapid acute stabilisation, particularly for the patient in crisis who cannot afford to wait weeks for TMS to work.
A 2025 PCN Reports analysis (Terao et al., PMID 40590032) reviewed comparative effectiveness data across intervention types for TRD and found no meaningful efficacy advantage for more invasive interventions over rTMS or IV ketamine — a finding relevant to treatment planning conversations in which electroconvulsive therapy might otherwise be introduced. For Julian’s position on ECT, see the reference article: ECT Side Effects and Alternatives.
What This Means for the Diagnostic Work-Up
A comparison between two symptomatic treatments only goes so far. Treatment-resistant depression is a clinical syndrome, not a single disease. Before committing a patient to a repeated course of either rTMS or esketamine, the responsible clinical approach is to ask why the brain is not responding to conventional treatment:
- Network mapping: qEEG and functional neuroimaging can identify specific prefrontal targets and connectivity patterns that inform TMS coil positioning and frequency parameters. The right target — not the average target — produces the best results.
- Inflammatory load: Elevated CRP, cytokines, and markers of neuroimmune activation predict poor antidepressant response and may point to a specific intervention before or alongside neurostimulation. See: Inflammation in Depression: When to Test CRP.
- Occult infections: Lyme disease, Bartonella, reactivated Epstein-Barr, and other stealth infections can produce a neuropsychiatric syndrome indistinguishable from treatment-resistant MDD. See: Bartonella Neuropsychiatric Syndrome.
- Relationship environment: An ongoing abusive or coercive relationship is not a brain disease and will not respond to brain stimulation. See: Narcissistic Abuse as a Driver of Treatment-Resistant Depression.
Both rTMS and esketamine treat the fire without asking what lit it. For some patients that is sufficient. For many patients with true treatment resistance, the cause needs to be found before the treatment can work.
Related Articles
- Ketamine as a Bridge to TMS: The Induction Protocol — The combined protocol that uses IV ketamine’s rapid action to cover the rTMS induction window.
- TMS for Depression: Clinical Guide — Full protocol overview: indications, targeting, session structure, and expected outcomes.
- Inflammation in Depression: When to Test CRP and What to Do with the Result — Elevated CRP predicts poor antidepressant and rTMS response; the lab work-up that should precede neuromodulation.
- ECT Side Effects and Alternatives — Why ECT should not be the default escalation step, and what the evidence shows.
- Narcissistic Abuse as an Overlooked Driver of Treatment-Resistant Depression — The relational factor that laboratory tests and brain scans miss.
References
-
Kaster TS, Haber E, Blumberger DM, et al. Efficacy of intranasal esketamine versus rTMS for treatment-resistant depression: analysis of individual participant data from two clinical trials. eClinicalMedicine. 2025 Oct 30;90:103609. PMID: 41245530
-
Hsu TW, Chu CS, Tsai SJ, et al. Comparison of rTMS and esketamine for treatment-resistant depression: A target trial emulation. J Affect Disord. 2025. PMID: 41506390
-
Ortiz-Canul A, García-de la Torre J, et al. Fast-acting approaches for treatment-resistant depression: real-world comparative effectiveness of intranasal esketamine versus accelerated rTMS. J Psychiatr Res. 2025. PMID: 41814584
-
Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683–1692. PMID: 29726344
-
Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study (TRANSFORM-2). Am J Psychiatry. 2019 Jun 1;176(6):428–438. PMID: 31109201
-
Terao I, Hikida T, Hirano J, et al. Comparative effectiveness of non-pharmacological interventions for treatment-resistant depression: a systematic review and network meta-analysis. PCN Rep. 2025. PMID: 40590032